Emergence of multidrug resistance in Campylobacter jejuni isolates from three patients infected with human immunodeficiency virus.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Emergence of multidrug resistance in Campylobacter jejuni isolates from three patients infected with human immunodeficiency virus.

Clin Infect Dis. 1995 Sep;21(3):634-8. Unique Identifier : AIDSLINE MED/96077386
Tee W; Mijch A; Wright E; Yung A; Victorian Infectious Diseases Reference Laboratory, Fairfield; Hospital, Victoria, Australia.

Abstract: Single-drug resistance to tetracycline, doxycycline, erythromycin, or fluoroquinolones in Campylobacter isolates recovered from humans has been documented worldwide. Multidrug resistance to these antibiotics is rare in Campylobacter jejuni. We report the sequential development of multidrug resistance in C. jejuni isolates from three patients who were infected with human immunodeficiency virus. Multiple isolates recovered from stool specimens from these patients were ribotyped, and antibiotic susceptibility profiles were determined. The results indicated that each patient was infected with a single strain of C. jejuni that had progressively acquired resistance to the antibiotics used during treatment. The emergence of resistant isolates appeared to correlate with clinical relapse. In these patients, campylobacter enteritis was prolonged, severe, and relapsing, and antimicrobial therapy was required. Once these first-line antibiotics become ineffective, few other antibiotics are available for treating patients with campylobacter enteritis. Acquisition of antibiotic resistance in C. jejuni is therefore of concern in these cases.

Keywords: Adult Anti-Infective Agents, Fluoroquinolone/PHARMACOLOGY Antibiotics, Macrolide/PHARMACOLOGY AIDS-Related Opportunistic Infections/DRUG THERAPY/*MICROBIOLOGY Campylobacter jejuni/*DRUG EFFECTS/ISOLATION & PURIF Campylobacter Infections/*COMPLICATIONS/DRUG THERAPY/MICROBIOLOGY Case Report Ciprofloxacin/PHARMACOLOGY Doxycycline/PHARMACOLOGY *Drug Resistance, Multiple Enteritis/*COMPLICATIONS/DRUG THERAPY/MICROBIOLOGY Erythromycin/PHARMACOLOGY Human Male Tetracycline Resistance JOURNAL ARTICLE
960430
M9640830

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .